Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation.
Crusoe EQ, Higashi F, Martinez G, Bittencourt R, Pinto Neto JV, Sousa L, Santucci R, Magalhães RJP, Colli G, Nunes RFM, Ribeiro G, Nicacio J, Zanella KR, Kutner JM, Magalhaes A, Leao D, Hallack Neto AE, Braga W, Souza EG, Guimaraes AJAM, Durigon GS, Laks D, Maiolino A, Hungria VTM; GBRAM- (GRUPO BRASILEIRO DE MIELOMA).
Crusoe EQ, et al.
Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):118-124. doi: 10.1016/j.htct.2019.05.004. Epub 2019 Aug 12.
Hematol Transfus Cell Ther. 2020.
PMID: 31537476
Free PMC article.